RxDoctor Payments Data

Joanna Grzadziel, DO

Family Medicine · Leesport, PANPI 1073900270

Payments from drug & device makers

$1,795in general payments, 2019–2025

Across 110 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$205
  • Novo Nordisk$200
  • Lilly USA, LLC$198
  • Boehringer Ingelheim$186
  • Pfizer$166
  • AstraZeneca$160
  • plus $680 from 11 others

What the payments were for

  • Food & beverage$1,788100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,795 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$118,124
Medicare patients
301
Services billed
2,165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide79$134,302
JardianceEmpagliflozin71$96,755
EliquisApixaban63$90,878
OzempicSemaglutide29$47,753
RybelsusSemaglutide23$39,390
JanuviaSitagliptin Phosphate24$25,322
XareltoRivaroxaban22$23,011
MounjaroTirzepatide17$20,890
SynjardyEmpagliflozin/Metformin Hcl14$11,737
OxycontinOxycodone Hcl18$11,091
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$10,296
Synjardy XrEmpagliflozin/Metformin Hcl14$10,239
ArexvyRsvpref3 Antigen/As01e/Pf30$9,422
MyrbetriqMirabegron14$8,279
SynthroidLevothyroxine Sodium88$7,204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$198$155,19296 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$186$118,73199 claims
PfizerEliquis$166$90,87863 claims
Novo NordiskOzempic, Rybelsus$200$87,14352 claims
MerckJanuvia, Janumet$71$31,22235 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$110$23,27759 claims
Johnson & JohnsonXarelto$17$23,01122 claims
AbbVieSynthroid, Linzess$205$13,88899 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Leesport

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →